We sought to characterise the impact of GLP‐1RA on adverse liver outcomes (ALO) among patients with alcohol‐associated liver disease (ALD) and Type 2 diabetes mellitus (T2DM). Click to show full abstract
We sought to characterise the impact of GLP‐1RA on adverse liver outcomes (ALO) among patients with alcohol‐associated liver disease (ALD) and Type 2 diabetes mellitus (T2DM).
               
Click one of the above tabs to view related content.